Alnylam Pharmaceuticals granted the Medicines Company the right to develop and market a series of RNA interference-based, cholesterol-lowering drug candidates. The deal covers ALN-PCS02, an experimental intravenous RNAi treatment, and ALN-PCSsc, a preclinical injectable RNAi candidate. Alnylam will get $25 million immediately and as much as $180 million in potential milestone fees plus sales royalties.